Kirsten rat sarcoma viral oncogene homolog G12V peptide–HLA-A*11:01 complex (KRAS G12V–HLA-A*11 complex)

The Kirsten rat sarcoma viral oncogene homolog G12V peptide–HLA-A*11:01 complex is a tumor-specific antigenic complex formed when the cancer-associated KRAS G12V mutant peptide is presented on the cell surface by the HLA-A*11:01 major histocompatibility complex class I molecule[1][5]. This complex serves as a neoantigen, uniquely present on tumor cells harboring the KRAS G12V mutation and the HLA-A*11:01 allele, enabling highly specific recognition by engineered T cell receptors[1][5]. As such, it is an actionable target for next-generation immunotherapies, including TCR-engineered T cell therapies and T cell engager molecules, offering potent anti-cancer effects with the potential for precision and safety[1][5]. The parent protein, KRAS, is a small GTPase that drives cell proliferation and survival in many cancers, and mutations at codon 12 (such as G12V) are among the most frequent oncogenic drivers in solid tumors[1][2][3][4][5]. Notes on structure and naming: - KRAS G12V refers to a glycine-to-valine substitution at position 12 in the KRAS protein. - HLA-A*11:01 is a specific human leukocyte antigen required for peptide presentation and TCR recognition. - The complex is what T cell receptors recognize in the context of immunotherapies; other drugs typically target KRAS protein itself. - This is a validated and specific immunological target, but how commonly it is referenced in drug databases as a “target” may vary—the canonical “parent” is Kirsten rat sarcoma viral oncogene homolog G12V (KRAS G12V). If more generalized, the canonical entry should be: - Canonical full name: Kirsten rat sarcoma viral oncogene homolog G12V - Canonical abbreviation: KRAS G12V - (The HLA restriction is important for immunotherapies, but the “target” for standard annotation is usually the mutant protein.)

Other names

KRAS G12V–HLA-A*11:01 complexKRAS G12V neoantigen–HLA-A11 complexKRAS G12V peptide–HLA-A*11:01

Adoptive T cell therapies (TCR-T): Engineered T cells express TCRs that specifically recognize the KRAS G12V peptide presented by HLA-A*11:01 on tumor cells, leading to targeted cytotoxicity and cytokine release against cancer cells[1][5].